Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 19/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31114270 | 0.90 | OPRM1 (0.43) | OPRM1OPRD1OPRK1KCNH2SCN5A | |
| SCHEMBL12541461 | 0.90 | OPRM1 (0.43) | OPRM1OPRD1OPRK1KCNH2SCN5A | |
| SCHEMBL28272416 | 0.85 | OPRM1 (0.40) | OPRM1OPRD1OPRK1KCNH2SCN5A | |
| SCHEMBL20825758 | 0.85 | OPRM1 (0.34) | MEN1GAAKMT2ASMN1; SMN2OPRM1 | |
| SCHEMBL29808294 | 0.85 | OPRM1 (0.34) | MEN1GAAKMT2ASMN1; SMN2OPRM1 | |
| SCHEMBL1812491 | 0.84 | MEN1 (0.52) | MEN1GAAKMT2ASMN1; SMN2 | |
| SCHEMBL25007168 | 0.83 | OPRM1 (0.38) | OPRM1OPRD1OPRK1KCNH2SCN5A | |
| SCHEMBL28272471 | 0.82 | OPRM1 (0.39) | OPRM1OPRD1OPRK1KCNH2SCN5A | |
| SCHEMBL11920606 | 0.82 | SMN1; SMN2 (0.47) | MEN1GAAKMT2ASMN1; SMN2 | |
| SCHEMBL29968127 | 0.82 | OPRM1 (0.41) | OPRM1OPRD1OPRK1KCNH2SCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3686198-B1 | MU-OPIOID RECEPTOR AGONIST AND PREPARATION METHOD THEREFOR AND USE THEREOF IN FIELD OF MEDICINE | SHANGHAI SYNERGY PHARMACEUTICAL SCIENCES CO LTD (CN) | 2022-12-14 | — | — | EP | disclosed |
| US-11072601-B2 | μ-opioid receptor agonist and preparation method therefor and use thereof in field of medicine | SHANGHAI SYNERGY PHARMACEUTICAL SCIENCES CO., LTD. (CN) | 2021-07-27 | — | — | US | disclosed |
| US-20200270230-A1 | µ-OPIOID RECEPTOR AGONIST AND PREPARATION METHOD THEREFOR AND USE THEREOF IN FIELD OF MEDICINE | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. (CN) | 2020-08-27 | — | — | US | disclosed |
| EP-3686198-A1 | mu-OPIOID RECEPTOR AGONIST AND PREPARATION METHOD THEREFOR AND USE THEREOF IN FIELD OF MEDICINE | Shanghai Synergy Pharmaceutical Sciences Co., Ltd (CN) | 2020-07-29 | — | — | EP | disclosed |
| WO-2019052557-A1 | μ-OPIOID RECEPTOR AGONIST AND PREPARATION METHOD THEREFOR AND USE THEREOF IN FIELD OF MEDICINE | 上海华汇拓医药科技有限公司 | 2019-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11072601-B2 | μ-opioid receptor agonist and preparation method therefor and use thereof in field of medicine | OPRM1, OPRD1, OPRK1 | MEN1 4231/4885GAA 3312/4885KMT2A 3540/4885 |
| US-20200270230-A1 | µ-OPIOID RECEPTOR AGONIST AND PREPARATION METHOD THEREFOR AND USE THEREOF IN FIELD OF MEDICINE | OPRM1, OPRD1, OPRK1 | MEN1 4382/4885GAA 3368/4885KMT2A 3545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.